Programme For The Third International DDI Workshop At Marbach Castle, Germany Finalized
The organisation team reports the final programme of the DDI 2012 - 3rd International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions.
Online, March 27, 2012 (Newswire.com) - The organisation team reports the final programme of the DDI 2012 - 3rd International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions.
The topics of the 3rd Marbach Castle meeting, which will take place from May 6th to 8th 2012, will be covered by international scientists and distinguished experts from academia, pharmaceutical companies, contract research organizations, consultancies and regulatory bodies. The programme will provide a unique opportunity for scientific exchange and networking across company and organizational borders, and an opportunity to learn about the current state-of-the-art in the investigation of DDIs.
The scientific sessions will cover different aspects to current regulatory regulations, UGT-based DDIs, non-metabolic/non-transport DDIs, transporter-based DDIs and pharmacodynamic DDIs. As before the 3rd DDI workshop will be truly international again. The speakers are coming from seven countries (USA, Germany, UK, Finland, Sweden, Japan and New Zealand), with a total of five speakers from the USA. Robert Hermann, member of the organisation team, highlights: "We are extremely pleased to announce that Professor Dr. Lawrence Lesko, who worked nearly 20 years in the FDA's Center for Drug Evaluation and Research as the Director of Clinical Pharmacology, will present the recently issued FDA Draft Guideline on the investigation of drug interactions."
This international Workshop on drug-drug interactions is designed to meet the requirements and expectations of professionals from the pharmaceutical industry, contract research organizations, regulatory agencies and academia. Department heads, project managers, scientists and consultants in R&D, in regulatory affairs, pharmacokinetics, clinical pharmacology, exploratory medicine, clinical development, biostatistics, business development, medical communications and so forth should attend. All delegates are invited to contribute actively to the scientific discussions.
About the DDI Workshop Series
The DDI Workshop series is an initiative of cr.appliance in cooperation with Professor Hartmut Derendorf, Professor Amin Rostami-Hodjegan, and Dr. Oliver von Richter. The meetings take place in Marbach Castle Conference Centre, located at the Lake Constance, Germany.
The organizers of the DDI Workshops are:
• Professor Hartmut Derendorf, PhD FCP; College of Pharmacy, University of Florida, USA
• Dr. Robert Hermann, MD FCP; cr.appliance, Germany
• Professor Amin Rostami-Hodjegan, PhD FCP; Faculty of Medical and Human Sciences, University of Manchester, UK
• Dr. Oliver von Richter, PhD FCP; Dept. Exploratory Medicine, Merck Serono, Germany
Share:
Tags: DDI workshop, drug development, drug-drug interaction, FDA draft guideline, pharmaceutical research, regulatory aspects